In a regulatory filing, Twist Bioscience (TWST) CEO Emily Leproust disclosed the sale of 31,348 common shares of the company on October 6 a a price of $32.187 per share, or a total consideration of $1.01M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target lowered to $40 from $45 at Barclays
- Cathie Wood Loads Up on Klarna, Synopsys, and Rubrik, Trims Shopify and Roblox Stocks
- Cathie Wood’s ARK Investment buys 221.7K shares of Twist Bioscience today
- PRME, TWST, TEM: Cathie Wood Pours $1.9M Into Biotech, Cuts Stake in AI Stock
- Cathie Wood’s ARK Investment buys 47.7K shares of Twist Bioscience today